1 |
Doki T, Tarusawa T, Hohdatsu T, Takano T. In vivo antiviral effects of U18666A against type I feline infectious peritonitis virus. Pathogens 2020;9:67.
DOI
|
2 |
Marchler-Bauer A, Anderson JB, Derbyshire MK, DeWeese-Scott C, Gonzales NR, Gwadz M, et al. CDD: a conserved domain database for interactive domain family analysis. Nucleic Acids Res 2007;35:D237-D240.
DOI
|
3 |
Rizvi SM, Shakil S, Haneef M. A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians. EXCLI J 2013;12:831-857.
|
4 |
Fuhrmann J, Rurainski A, Lenhof HP, Neumann D. A new Lamarckian genetic algorithm for flexible ligand-receptor docking. J Comput Chem 2010;31:1911-1918.
|
5 |
Bogusz M, Whelan S. Phylogenetic tree estimation with and without alignment: new distance methods and benchmarking. Syst Biol 2017;66:218-231.
|
6 |
Sahoo M, Jena L, Rath SN, Kumar S. Identification of suitable natural inhibitor against influenza A (H1N1) neuraminidase protein by molecular docking. Genomics Inform 2016;14:96-103.
DOI
|
7 |
Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int 2014;2014:186864.
|
8 |
Ashfaq UA, Idrees S. Medicinal plants against hepatitis C virus. World J Gastroenterol 2014;20:2941-2947.
DOI
|
9 |
Mohan M, James P, Valsalan R, Nazeem PA. Molecular docking studies of phytochemicals from Phyllanthus niruri against hepatitis B DNA polymerase. Bioinformation 2015;11:426-431.
DOI
|
10 |
Jagadeb M, Rath SN, Sonawane A. In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis. J Biomol Struct Dyn 2019;37: 3388-3398.
DOI
|
11 |
Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B 2020;10:1228-1238.
DOI
|
12 |
Sarma P, Shekhar N, Prajapat M, Avti P, Kaur H, Kumar S, et al. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn 2020 May 18 [Epub]. https://doi.org/10.1080/07391102.2020.1753580.
DOI
|
13 |
Kaliyaperumal S, Periyasamy K, Balakrishnan U, Palanivel P, Egbuna C. Antiviral phytocompounds for drug development: a data mining studies. In: Phytochemicals as Lead Compounds for New Drug Discovery (Egbuna C, Kumar S, Ifemeje J, Ezzat S, Kaliyaperumal S, eds.). Amsterdam: Elsevier, 2020. pp. 239-244.
|
14 |
Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 2007;74:92-101.
DOI
|
15 |
Kadioglu O, Saeed M, Johannes Greten H, Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Preprint at http://dx.doi.org/10.2471/BLT.20.255943 (2020).
|
16 |
Calligari P, Bobone S, Ricci G, Bocedi A. Molecular investigation of SARS-CoV-2 proteins and their interactions with antiviral drugs. Viruses 2020;12:445.
DOI
|
17 |
Chen R, Lin J, Hong J, Han D, Zhang AD, Lan R, et al. Potential toxicity of quercetin: the repression of mitochondrial copy number via decreased POLG expression and excessive TFAM expression in irradiated murine bone marrow. Toxicol Rep 2014;1:450-458.
DOI
|
18 |
Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31:69-75.
|
19 |
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020;11:1620.
DOI
|
20 |
Johns C. Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars. CJEM 2009;11:94-96.
DOI
|
21 |
Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181:894-904.
DOI
|
22 |
McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses 2014;6:2991-3018.
DOI
|
23 |
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020;9:29.
DOI
|
24 |
Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARSCoV-2 and other human coronaviruses. Trends Immunol 2020;41:355-359.
DOI
|
25 |
Lin SM, Lin SC, Hsu JN, Chang CK, Chien CM, Wang YS, et al. Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design. J Med Chem 2020;63:3131-3141.
DOI
|
26 |
Alhazmi MI. Molecular docking of selected phytocompounds with H1N1 proteins. Bioinformation 2015;11:196-202.
DOI
|
27 |
Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 2016;33:1870-1874.
DOI
|
28 |
Buchan DW, Jones DT. The PSIPRED Protein Analysis Workbench: 20 years on. Nucleic Acids Res 2019;47:W402-W407.
DOI
|
29 |
Huang B. MetaPocket: a meta approach to improve protein ligand binding site prediction. OMICS 2009;13:325-330.
DOI
|
30 |
Bhowmik D, Nandi R, Jagadeesan R, Kumar N, Prakash A, Kumar D. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Infect Genet Evol 2020;84:104451.
DOI
|
31 |
Yang P, Wang X. COVID-19: a new challenge for human beings. Cell Mol Immunol 2020;17:555-557.
DOI
|
32 |
Rafe T, Shawon PA, Salem L, Chowdhury NI, Kabir F, Bin Zahur SM, et al. Preventive role of resveratrol against inflammatory cytokines and related diseases. Curr Pharm Des 2019;25:1345-1371.
DOI
|